Advertisement
U.S. markets closed

CymaBay Therapeutics, Inc. (CBAY)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
32.480.00 (0.00%)
At close: 04:00PM EDT
  • Delisting

    CBAY is delisted effective Apr. 1, 2024

Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close32.48
Open0.00
Bid32.47 x 2000
Ask32.49 x 6600
Day's Range32.48 - 32.48
52 Week Range7.26 - 32.50
Volume0
Avg. Volume3,971,638
Market Cap3.728B
Beta (5Y Monthly)0.32
PE Ratio (TTM)N/A
EPS (TTM)-0.99
Earnings DateMay 13, 2024 - May 17, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est32.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for CBAY

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • CymaBay Therapeutics Inc.
    ENTA: Lowering target price to $77.00ENANTA PHARMACEUTICALS INC has an Investment Rating of BUY; a target price of $77.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of High; and a Value Subrating of Medium.
    Rating
    Fair Value
    Economic Moat
    2 years agoArgus Research
View more